# Genetic Engineering Market

> Genetic Engineering Market Research Report Information By Product (Biochemical and Genetic Markers), By Devices (PCR, Gene Gun, and Gel Assemblies), By Techniques (Artificial Selection and Gene Splicing), By Application (Agriculture and Medical Industry), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 20.94%
- **2024:** $ 1.68 Billion
- **2025:** $ 2.03 Billion
- **2035:** $ 13.6 Billion
- **Key Players:** Monsanto (US), Syngenta (CH), BASF (DE), DuPont (US), Corteva (US), Regeneron Pharmaceuticals (US), Amgen (US), Genentech (US), CRISPR Therapeutics (CH), Editas Medicine (US)

**Report ID:** MRFR/LS/0999-HCR · **Pages:** 140 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528

---

## Market Summary

As per Market Research Future analysis, The Global Genetic Engineering Market Size was estimated at 1.68 USD Billion in 2024. The genetic engineering industry is projected to grow from 2.032 USD Billion in 2025 to 13.6 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 20.94% during the forecast period 2025 - 2035

## Market Drivers

### Growing Investment in Biotechnology Research

Investment in biotechnology research is a significant driver of The Global Genetic Engineering Industry. Governments and private entities are increasingly allocating funds to support research initiatives aimed at developing novel genetic engineering applications. For instance, funding for agricultural biotechnology research has seen a marked increase, with investments reaching over USD 5 billion annually. This financial backing facilitates the exploration of new genetic engineering techniques and the development of products that can address pressing global challenges, such as climate change and food security. As research continues to advance, The Global Genetic Engineering Industry is likely to benefit from a steady influx of innovative solutions that enhance productivity and sustainability.

### Rising Demand for Genetically Modified Organisms

The increasing demand for genetically modified organisms (GMOs) is a pivotal driver in The Global Genetic Engineering Industry. As populations grow, the need for enhanced agricultural productivity becomes paramount. GMOs are engineered to exhibit traits such as pest resistance and improved nutritional content, which can lead to higher crop yields. According to recent data, the market for GMOs is projected to reach USD 40 billion by 2025, reflecting a compound annual growth rate of approximately 10%. This surge is largely attributed to the agricultural sector's quest for sustainable solutions to food security challenges. Consequently, The Global Genetic Engineering Industry is witnessing a robust expansion as stakeholders seek innovative ways to meet consumer demands and environmental sustainability goals.

### Technological Innovations in Genetic Engineering

Technological advancements play a crucial role in shaping The Global Genetic Engineering Industry. Innovations such as CRISPR-Cas9 and other gene-editing technologies have revolutionized the field, enabling precise modifications at the genetic level. These technologies not only enhance the efficiency of genetic engineering processes but also reduce the time and costs associated with research and development. The market for gene editing technologies is expected to grow significantly, with estimates suggesting a valuation of USD 10 billion by 2026. This growth is indicative of the increasing adoption of these technologies across various sectors, including agriculture, healthcare, and industrial biotechnology. As a result, The Global Genetic Engineering Industry is poised for substantial growth driven by these cutting-edge innovations.

### Consumer Acceptance of Genetically Engineered Products

Consumer acceptance is a vital factor influencing The Global Genetic Engineering Industry. As awareness of the benefits of genetically engineered products grows, consumers are becoming more receptive to their use. This shift in perception is crucial for the market's expansion, as it encourages manufacturers to invest in the development of genetically modified foods and other products. Surveys indicate that approximately 60% of consumers are willing to purchase genetically modified foods if they are proven to be safe and beneficial. This growing acceptance is likely to drive demand, leading to increased production and innovation within The Global Genetic Engineering Industry, ultimately fostering a more sustainable food system.

### Regulatory Support for Genetic Engineering Initiatives

Regulatory frameworks are increasingly supportive of genetic engineering initiatives, serving as a key driver in The Global Genetic Engineering Industry. Governments worldwide are recognizing the potential benefits of genetic engineering in addressing food security and environmental challenges. As a result, many countries are streamlining their regulatory processes to facilitate the approval of genetically modified products. For example, the European Union has recently proposed reforms aimed at expediting the approval of gene-edited crops. Such regulatory support not only encourages innovation but also instills confidence among investors and stakeholders in The Global Genetic Engineering Industry. This trend is likely to enhance the market's growth prospects as more products gain regulatory approval.

## Future Outlook

The Global Genetic Engineering Market is projected to grow at a 20.94% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing agricultural demands, and healthcare innovations.

**New opportunities:**

- Development of CRISPR-based therapeutics for rare diseases.
- Expansion of genetically modified crops for sustainable agriculture.
- Investment in [bioinformatics](https://www.marketresearchfuture.com/reports/bioinformatics-market-2265) platforms for genetic data analysis.

By 2035, the market is expected to be robust, driven by innovation and strategic investments.

## Segment Insights

### By Product: Biochemical (Largest) vs. Genetic Markers (Fastest-Growing)

The Global Genetic Engineering exhibits a clear distinction in market share between its major product segments. The Biochemical segment stands out as the largest contributor, showcasing a robust adoption across various applications such as pharmaceuticals, agriculture, and environmental management. In contrast, the Genetic Markers segment, while smaller in overall share, is rapidly gaining traction due to advancements in precision medicine and biotechnology research, indicating strong future potential. 
Growth trends in this segment are primarily driven by the increasing need for innovative solutions in healthcare and agriculture. The Biochemical sector benefits from established technologies and a diverse application range, whereas the rapid growth of Genetic Markers is fueled by rising investments in genomics and [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), highlighting a shift towards more tailored therapeutic approaches.

Biochemical (Dominant) vs. Genetic Markers (Emerging)

The Biochemical segment is characterized by its mature market presence and widespread use in various industries, including pharmaceuticals and agriculture. With established processes in place, this segment leverages a range of bioproducts that enhance productivity and efficiency. In contrast, the Genetic Markers segment is emerging, driven by innovations in genomics and an increasing emphasis on personalized medicine. This segment focuses on identifying genetic variations that influence disease susceptibility and treatment responses, catering to the evolving demands of the healthcare sector. As research intensifies in genomics, the market position of Genetic Markers is expected to strengthen, fostering collaboration between technology providers and healthcare professionals.

### By Devices: PCR (Largest) vs. Gene Gun (Fastest-Growing)

The Global Genetic Engineering's 'Devices' segment sees a substantial distribution of market share among PCR, Gene Gun, and Gel Assemblies. PCR dominates this segment, holding the largest share due to its widespread application in diagnostics and research, proving essential for genetic amplification. Meanwhile, the Gene Gun is gaining traction as a key player, especially in plant transformation and gene delivery, thereby capturing significant attention from researchers and agricultural developers.

Devices: PCR (Dominant) vs. Gene Gun (Emerging)

PCR technology continues to be the dominant force in the devices segment of The Global Genetic Engineering, thanks to its established efficacy in amplifying DNA for various applications such as cloning, gene expression analysis, and medical diagnostics. In contrast, the Gene Gun represents an emerging technology, increasingly recognized for its ability to deliver foreign genes into plant cells and tissues efficiently, thus supporting advancements in agricultural biotechnology. As researchers increasingly explore innovative genetic applications, the adoption of Gene Gun technology is expected to rise, driven by ongoing agricultural challenges and the pursuit of genetically modified crops.

### By Technique: Gene Splicing (Largest) vs. Artificial Selection (Fastest-Growing)

In The Global Genetic Engineering, Gene Splicing holds the largest market share, significantly overshadowing other techniques with its advanced capabilities and widespread applications in agriculture, medicine, and biotechnology. Meanwhile, Artificial Selection, although smaller in market share, is witnessing a rapid increase in adoption, as more researchers and organizations recognize its potential in enhancing desirable traits in species without the intricate processes associated with gene editing technologies.

Technique: Gene Splicing (Dominant) vs. Artificial Selection (Emerging)

Gene Splicing is the dominant technique in the genetic engineering landscape, offering precise manipulation of genetic material to create organisms with targeted traits. Its applications range from developing disease-resistant crops to [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) in humans, making it a critical tool in various sectors. Conversely, Artificial Selection, while currently an emerging technique, is gaining traction due to its accessibility and ease of application. This method relies on the traditional practice of selecting parents for breeding based on desirable characteristics, enabling quicker results than molecular methods. As demand for ethical and efficient genetic manipulation grows, both techniques will likely play pivotal roles, albeit with Gene Splicing leading the way.

### By Application: Agriculture (Largest) vs. Medical Industry (Fastest-Growing)

In The Global Genetic Engineering, the application segment is primarily dominated by agriculture, which captures the largest share due to the rising demand for genetically modified crops that enhance yield and resistance to pests. The agricultural application of genetic engineering has become prevalent as it offers innovative solutions to food security and sustainability challenges, leading to an increased adoption among farmers and agricultural organizations. In contrast, the medical industry, while currently smaller in market share, is gaining traction as advancements in gene editing technologies and therapies drive its growth.

Application: Agriculture (Dominant) vs. Medical Industry (Emerging)

The agriculture application of genetic engineering plays a pivotal role in revolutionizing farming practices. Genetically modified organisms (GMOs) improve crop resilience, increase productivity, and reduce dependency on chemical pesticides. This segment is characterized by extensive research and a focus on sustainability, making it a dominant force in the market. On the other hand, the medical industry is emerging rapidly due to innovations such as CRISPR and gene therapy, which promise significant advancements in treating genetic disorders and diseases. This sector is fueled by substantial investment and research efforts, indicating its growing importance and potential in the genetic engineering landscape.

## Regional Market Share Analysis

### North America : Innovation and Investment Hub

North America dominates The Global Genetic Engineering Market, accounting for approximately 45% of the total market share. The region benefits from robust investment in biotechnology, strong research and development initiatives, and favorable regulatory frameworks. The increasing demand for genetically modified organisms (GMOs) in agriculture and healthcare is driving growth, supported by government policies that encourage innovation and commercialization of genetic technologies. The United States is the largest market, followed by Canada, both of which host major players like Monsanto, DuPont, and Corteva. The competitive landscape is characterized by significant mergers and acquisitions, as companies seek to enhance their product offerings and market reach. The presence of leading research institutions further strengthens the region's position, fostering collaboration between academia and industry.

### Europe : Regulatory Framework and Innovation

Europe is witnessing significant growth in the genetic engineering market, holding approximately 30% of the global share. The region's growth is driven by increasing investments in agricultural biotechnology and a strong focus on sustainable practices. Regulatory frameworks, such as the European Union's stringent guidelines on GMOs, are shaping market dynamics, encouraging innovation while ensuring safety and environmental protection. Germany and France are the leading countries in this sector, with a strong presence of key players like BASF and Syngenta. The competitive landscape is marked by collaborations between biotech firms and research institutions, enhancing the development of innovative solutions. The European market is also characterized by public awareness and acceptance of genetic engineering, which is crucial for future growth.

### Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is rapidly emerging as a significant player in The Global Genetic Engineering Market, accounting for about 20% of the total market share. The region's growth is fueled by increasing agricultural demands, population growth, and the need for food security. Countries like China and India are investing heavily in biotechnology research and development, supported by government initiatives aimed at enhancing agricultural productivity through genetic engineering. China is the largest market in the region, with a focus on developing genetically modified crops to meet domestic food needs. The competitive landscape includes both local and international players, with companies like CRISPR Therapeutics and Editas Medicine making strides in the market. The region's diverse agricultural landscape presents unique opportunities for genetic engineering applications, driving innovation and adoption across various sectors.

### Middle East and Africa : Emerging Market with Potential

The Middle East and Africa region is gradually emerging in the genetic engineering market, holding approximately 5% of the global share. The growth is driven by increasing agricultural challenges, such as drought and food security concerns, prompting governments to explore genetic engineering solutions. Initiatives to enhance crop resilience and productivity are gaining traction, supported by international collaborations and funding. South Africa is the leading country in this region, with a focus on biotechnology in agriculture. The competitive landscape is characterized by a mix of local startups and international firms looking to expand their presence. The region's unique challenges present opportunities for innovative genetic engineering applications, particularly in developing drought-resistant crops and improving livestock genetics.

## Competitive Benchmarking

Leading market players are largely investing in research and development to expand their product lines, which will help the genetic engineering market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their global presence. The genetic engineering industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the global genetic engineering industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the genetic engineering industry has stipulated some of the most important medicinal benefits.  Major players in the genetic engineering industry, including Precision Biosciences, Intellia Therapeutics Inc., Merck KGaA, Sangamo, Thermo Fisher Scientific Inc, and others, are funding operations for research and development to boost market demand.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical business focused on altering the daily lives of patients suffering from devastating diseases by developing next-generation, genome-edited cell therapies based on its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA). The company operates and manages its operations as a single reportable operating segment, which involves the development of an allogeneic CAR-T and CAR-NK cell therapy pipeline.

In May  Caribou Science engaged in a commercial and clinical license arrangement with MaxCyte. The agreement sought exclusive use of MaxCyte's flow electroporation technology and the ExPERT platform.

Caribou's gene-edited allogeneic T-cell treatment programs progressed due to this strategy, as were its business relationships in the genetic engineering sector.

Thermo Fisher Scientific Inc. is an American manufacturer and distributor of scientific instruments, reagents, consumables, and software services. Thermo Fisher, headquartered in Waltham, Massachusetts, was founded in 2006 by merging Thermo Electron and Fisher Scientific.  Scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents are all available from Thermo Fisher Scientific.

In April  Thermo Fisher Scientific released a new Gibco CTS TrueCut Cas9 Protein, as high-quality support material and documents are vital as genome editing researchers progress from fundamental research to therapeutic settings.

It is a viable approach for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it routinely achieves greater than 90% efficacy in human primary T-cells and high editing effectiveness in all cell lines tested.

## Recent News & Developments

**April 2023** Ginkgo Bioworks, which is developing the leading platform for cell programming and biosecurity, announced the acquisition of StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets, with a secondary close scheduled upon the transfer to Ginkgo of certain additional in-license agreements. Ginkgo will combine these skills and intellectual property into its end-to-end AAV gene therapy development platform, enabling Ginkgo's customers to make use of new tools to target a wide range of tissue types effectively.

**October 2021** Merck Life Science has licensed its proprietary CRISPR-Cas9 technology to Cellecta to develop next-generation medicines. The technology's licensing enables researchers and scientists to develop remedies for hereditary blood problems, malignancies, and ophthalmological ailments.

## Report Scope

| MARKET SIZE 2024 | 1.68(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.032(USD Billion) |
| MARKET SIZE 2035 | 13.6(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.94% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Monsanto (US), Syngenta (CH), BASF (DE), DuPont (US), Corteva (US), Regeneron Pharmaceuticals (US), Amgen (US), Genentech (US), CRISPR Therapeutics (CH), Editas Medicine (US) |
| Segments Covered | Product, Devices, Techniques, Application, Region |
| Key Market Opportunities | Advancements in gene editing technologies create transformative opportunities in The Global Genetic Engineering. |
| Key Market Dynamics | Rising regulatory scrutiny and technological advancements drive innovation and competition in the genetic engineering sector. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of The Global Genetic Engineering by 2035?**
A: The projected market valuation for The Global Genetic Engineering is expected to reach 13.6 USD Billion by 2035.

**Q: What was the market valuation of The Global Genetic Engineering in 2024?**
A: The overall market valuation was 1.68 USD Billion in 2024.

**Q: What is the expected CAGR for The Global Genetic Engineering during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Genetic Engineering during the forecast period 2025 - 2035 is 20.94%.

**Q: Which companies are considered key players in The Global Genetic Engineering?**
A: Key players in the market include Monsanto, Syngenta, BASF, DuPont, Corteva, Regeneron Pharmaceuticals, Amgen, Genentech, CRISPR Therapeutics, and Editas Medicine.

**Q: What are the main product segments in The Global Genetic Engineering?**
A: The main product segments include Biochemical and Genetic Markers, with valuations of 0.84 USD Billion and 6.72 USD Billion, respectively.

**Q: What devices are included in The Global Genetic Engineering, and what are their valuations?**
A: Devices in the market include PCR, Gene Gun, and Gel Assemblies, with valuations of 0.5 USD Billion, 0.4 USD Billion, and 0.78 USD Billion, respectively.

**Q: What techniques are utilized in The Global Genetic Engineering?**
A: The techniques utilized include Artificial Selection and Gene Splicing, both valued at 0.84 USD Billion and 6.8 USD Billion.

**Q: In which applications is genetic engineering primarily used?**
A: Genetic engineering is primarily applied in Agriculture and the Medical Industry, each valued at 0.84 USD Billion and 6.8 USD Billion.

**Q: How does the market performance of genetic engineering in 2025 compare to 2024?**
A: The market performance in 2025 is anticipated to show substantial growth compared to the 1.68 USD Billion valuation in 2024.

**Q: What trends are expected to shape The Global Genetic Engineering in the coming years?**
A: Trends likely to shape the market include advancements in biotechnology, increased investment from key players, and growing applications in various industries.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528*